KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
KYSA-6: A Phase 2/3, Open-Label, Randomized, Controlled, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-cell (CD19 CAR T) Therapy, Versus Ongoing Standard-Of-Care Immunosuppressive Therapy in Patients With Generalized Myasthenia Gravis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Kyverna Therapeutics, Inc.
- Phone Number: 510-925-2484
- Email: Clinicaltrials@kyvernatx.com
Study Locations
-
-
-
Westmead, Australia
- Recruiting
- Westmead Institute for Medical Research
-
Contact:
- Study Coordinator
-
-
-
-
-
São Paulo, Brazil
- Recruiting
- Hospital israelita Albert Einstein
-
Contact:
- Study Coordinator
-
-
-
-
-
Berlin, Germany
- Recruiting
- Charite- Universitätsklinikum Berlin
-
Contact:
- Study Coordinator
-
Bochum, Germany
- Recruiting
- Universitätsklinikum der Ruhr-Universität Bochum
-
Contact:
- Study Coordinator
-
Hamburg, Germany
- Recruiting
- Universitätsklinikum Hamburg-Eppendorf
-
Contact:
- Study Coordinator
-
Hanover, Germany
- Recruiting
- Medizinische Hochscule Hannover
-
Contact:
- Study Coordinator
-
Jena, Germany
- Recruiting
- Friedrich-Schiller-Universität Jena
-
Contact:
- Study Coordinator
-
Magdeburg, Germany
- Recruiting
- Universitätsklinik Magdeburg
-
Contact:
- Study Coordinator
-
Munich, Germany
- Recruiting
- Technical University Munich, Klinikum Rechts der Isar
-
Contact:
- Study Coordinator
-
-
-
-
Kindom of Saudi Arabia
-
Riyadh, Kindom of Saudi Arabia, Saudi Arabia
- Recruiting
- King's Faisal Specialist Hospital and Research Center
-
Contact:
- Study Coordinator
-
-
-
-
-
Cambridge, United Kingdom
- Recruiting
- Cambridge University Hospital, Addenbrooke's Hospital
-
Contact:
- Study Coordinator
-
London, United Kingdom
- Recruiting
- King's College Hospital
-
Contact:
- Study Coordinator
-
-
-
-
California
-
Los Angeles, California, United States, 90095
- Recruiting
- Ronald Reagan UCLA Medical Center
-
Contact:
- Study Coordinator
-
Orange, California, United States, 92868
- Recruiting
- University of California, Irvine
-
Contact:
- Study Coordinator
-
Palo Alto, California, United States, 94305
- Recruiting
- Stanford University Medical Center
-
Contact:
- Study Coordinator
-
-
Florida
-
Miami, Florida, United States, 33149
- Recruiting
- University of Miami
-
Contact:
- Study Coordinator
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Recruiting
- Indiana University Health
-
Contact:
- Study Coordinator
-
-
Missouri
-
Columbia, Missouri, United States, 65212
- Recruiting
- University of Missouri
-
Contact:
- Study Coordinator
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Recruiting
- Oregon Health & Science University
-
Contact:
- Study Coordinatory
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Recruiting
- Thomas Jefferson University Hospital
-
Contact:
- Study Coordinator
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- Houston Methodist Hospital
-
Contact:
- Study Coordinator
-
-
Utah
-
Murray, Utah, United States, 84107
- Recruiting
- Intermountain Medical Center
-
Contact:
- Study Coordinator
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Key Inclusion Criteria
- Presence of autoantibodies to AChR or MuSK
- Myasthenia Gravis Foundation of America (MGFA) Class II-IV
- MG-Activities of Daily Living (MG-ADL) total score of ≥6 at screening and confirmed at baseline visit
- QMG total score of ≥11 at screening an confirmed at baseline visit
- Failed treatment with 2 or more immunosuppressive/immunomodulatory therapies, or failed at least 1 immunosuppressive therapy and required chronic plasmapheresis, or IVIG (or subcutaneous or intramuscular Ig) to control symptoms
- On a stable dose of glucocorticoids and/or other immunotherapies for ≥1 month prior to screening. For patients treated with azathioprine, a stable dose for ≥2 months prior to screening is required
- No change in dose of acetylcholinesterase inhibitors for ≥2 weeks prior to screening
- No use of intravenous immune globulin (IVIG) or plasmapheresis (PLEX) within 4 weeks of screening or pre-dose baseline (unless this is part of their SOC treatment regimen)
- No use of rituximab (or any other anti-CD20 or CD19 monoclonal antibody) within 12 weeks prior to screening
- Able and willing to attend the necessary visits to the study site
Key Exclusion Criteria
- Unable to washout or interrupt autoimmune disease therapy prior to apheresis and/or baseline if required
- Co-occurring neurological autoimmune disease (ie, Lambert-Eaton Myasthenic Syndrome) or any disease affecting the neuromuscular junction or muscle causing weakness (eg, myositis, myopathy, motor neuropathy)
- History of stroke (with residual sequalae and/or risk for recurrence), seizure (even if well controlled on antiepileptics), neurodegenerative disease, altered mental status (unexplained and/or recent/current), or uncontrolled/severe psychiatric disease
- Any serious and/or uncontrolled medical condition that, in the investigator's judgment, would cause unacceptable safety risk, interfere with study procedures or results, or compromise compliance with the protocol, including but not limited to, clinically significant cardiac or pulmonary disease
- History of primary immunodeficiency, organ or allogeneic bone marrow transplant, or splenectomy
- Active, uncontrolled, viral, bacterial, or systemic fungal infection or recent history of repeated infections
- Thymectomy <12 months of screening or planned during the study
- Prior treatment with gene therapy product or cellular immunotherapy (eg, CAR T) requiring vector integration and directed at any target
- Patients requiring chronic anticoagulation therapy that cannot be discontinued for medical procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: KYV-101 CAR-T cells with lymphodepletion conditioning
Phase 2: Dosing with KYV-101 CAR-T cells
|
Standard lymphodepletion regimen
Other Names:
Anti-CD19 CAR-T cell therapy
|
|
Experimental: KYV-101 Treatment
Phase 3
|
Standard lymphodepletion regimen
Other Names:
Anti-CD19 CAR-T cell therapy
|
|
Active Comparator: Standard of Care
Phase 3 Optional crossover to receive KYV-101 Treatment after 24 weeks
|
Standard lymphodepletion regimen
Other Names:
Anti-CD19 CAR-T cell therapy
Standard of Care Medications Optional Crossover to receive KYV-101 treatment
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Efficacy of KYV-101 via Myasthenia Gravis Activities of Daily Living (MG-ADL) change from baseline (Phase 2)
Time Frame: 24 weeks
|
24 weeks
|
|
Incidence and severity of adverse events (AEs) and laboratory abnormalities (Phase 2)
Time Frame: 18 months
|
18 months
|
|
Efficacy of KYV-101 via Myasthenia Gravis Activities of Daily Living (MG-ADL) change from baseline for KYV-101 Treatment arm to Standard of Care arm (Phase 3)
Time Frame: 24 weeks
|
24 weeks
|
|
Efficacy of KYV-101 via Quantitative Myasthenia Gravis (QMG) change from baseline for KYV-101 Treatment arm to Standard of Care arm (Phase 3)
Time Frame: 24 weeks
|
24 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Efficacy of KYV-101 via Percent change from baseline in anti acetylcholine receptors (anti-AChR) antibody levels for KYV-101 Treatment arm to Standard of Care arm (Phase 3)
Time Frame: 24 weeks
|
24 weeks
|
|
Efficacy of KYV-101 via Percent change from baseline in anti muscle-specific tyrosine kinase (anti-MuSK) antibody levels for KYV-101 Treatment arm to Standard of Care arm (Phase 3)
Time Frame: 24 weeks
|
24 weeks
|
|
Efficacy of KYV-101 via Proportion of patients with a ≥3 point improvement from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) for KYV-101 Treatment arm to Standard of Care arm (Phase 3)
Time Frame: 24 weeks
|
24 weeks
|
|
Efficacy of KYV-101 via Proportion of patients with minimal symptom expression (MSE) for KYV-101 Treatment arm to Standard of Care arm (Phase 3)
Time Frame: 24 weeks
|
24 weeks
|
|
Efficacy of KYV-101 via Myasthenia Gravis Quality of Life 15-item Scale (MG-QoL 15r) change from baseline for KYV-101 Treatment arm to Standard of Care arm (Phase 3)
Time Frame: 24 weeks
|
24 weeks
|
|
Efficacy of KYV-101 via Myasthenia Gravis Composite (MGC) score change from baseline for KYV-101 Treatment arm to Standard of Care arm (Phase 3)
Time Frame: 24 weeks
|
24 weeks
|
|
Incidence and severity of adverse events (AEs) and laboratory abnormalities (Phase 3)
Time Frame: 18 months
|
18 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: MD, Kyverna Therapeutics, Inc.
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neoplasms by Site
- Neoplasms
- Neuromuscular Diseases
- Immune System Diseases
- Autoimmune Diseases of the Nervous System
- Neurodegenerative Diseases
- Paraneoplastic Syndromes, Nervous System
- Nervous System Neoplasms
- Paraneoplastic Syndromes
- Neuromuscular Junction Diseases
- Myasthenia Gravis
- Autoimmune Diseases
- Organic Chemicals
- Hydrocarbons
- Phosphoramide Mustards
- Nitrogen Mustard Compounds
- Mustard Compounds
- Hydrocarbons, Halogenated
- Phosphoramides
- Organophosphorus Compounds
- Cyclophosphamide
- fludarabine
Other Study ID Numbers
Other Study ID Numbers
- KYSA-6
- KYV101-006 (Other Identifier: Kyverna Therapeutics)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.